Kelman Lazarov Inc. boosted its position in shares of Monsanto Company (NYSE:MON) by 5.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,747 shares of the basic materials company’s stock after buying an additional 546 shares during the period. Kelman Lazarov Inc.’s holdings in Monsanto were worth $1,154,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Raymond James Trust N.A. boosted its position in Monsanto by 95.1% in the first quarter. Raymond James Trust N.A. now owns 7,533 shares of the basic materials company’s stock worth $853,000 after buying an additional 3,671 shares during the period. Creative Planning boosted its position in Monsanto by 0.7% in the first quarter. Creative Planning now owns 24,709 shares of the basic materials company’s stock valued at $2,797,000 after buying an additional 171 shares during the period. Chesley Taft & Associates LLC bought a new position in Monsanto during the first quarter valued at $6,828,000. Gulf International Bank UK Ltd boosted its position in Monsanto by 1.2% in the first quarter. Gulf International Bank UK Ltd now owns 135,274 shares of the basic materials company’s stock valued at $15,313,000 after buying an additional 1,600 shares during the period. Finally, Augustine Asset Management Inc. boosted its position in Monsanto by 2.4% in the first quarter. Augustine Asset Management Inc. now owns 20,094 shares of the basic materials company’s stock valued at $2,274,000 after buying an additional 462 shares during the period. Institutional investors own 75.28% of the company’s stock.
Shares of Monsanto Company (NYSE MON) traded down 0.20% during trading on Friday, hitting $116.87. 2,081,472 shares of the stock traded hands. The firm has a 50-day moving average of $117.38 and a 200-day moving average of $115.36. The firm has a market capitalization of $51.34 billion, a price-to-earnings ratio of 25.24 and a beta of 1.07. Monsanto Company has a 1-year low of $97.35 and a 1-year high of $118.97.
Monsanto (NYSE:MON) last announced its earnings results on Wednesday, June 28th. The basic materials company reported $1.93 earnings per share for the quarter, topping analysts’ consensus estimates of $1.74 by $0.19. Monsanto had a net margin of 14.11% and a return on equity of 45.26%. The business had revenue of $4.23 billion during the quarter, compared to the consensus estimate of $4.18 billion. During the same quarter last year, the firm earned $2.17 earnings per share. Monsanto’s quarterly revenue was up 1.0% on a year-over-year basis. On average, equities analysts forecast that Monsanto Company will post $4.89 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, October 6th will be paid a dividend of $0.54 per share. This represents a $2.16 dividend on an annualized basis and a yield of 1.85%. The ex-dividend date of this dividend is Thursday, October 5th. Monsanto’s dividend payout ratio is presently 46.75%.
COPYRIGHT VIOLATION WARNING: “Kelman Lazarov Inc. Has $1.15 Million Position in Monsanto Company (NYSE:MON)” was published by BNB Daily and is owned by of BNB Daily. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/monsanto-company-nysemon-stake-boosted-by-kelman-lazarov-inc-updated.html.
Several research analysts recently weighed in on MON shares. Zacks Investment Research upgraded shares of Monsanto from a “hold” rating to a “buy” rating and set a $132.00 price objective for the company in a research report on Friday, June 16th. Vetr upgraded shares of Monsanto from a “hold” rating to a “buy” rating and set a $122.35 price objective for the company in a research report on Wednesday, July 12th. UBS AG cut shares of Monsanto from a “buy” rating to a “neutral” rating in a research report on Friday. BidaskClub cut shares of Monsanto from a “hold” rating to a “sell” rating in a research report on Sunday, July 16th. Finally, Royal Bank Of Canada restated a “sector perform” rating and issued a $128.00 price objective (up previously from $120.00) on shares of Monsanto in a research report on Thursday, June 29th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $123.15.
In related news, SVP Janet M. Holloway sold 7,423 shares of Monsanto stock in a transaction on Tuesday, June 13th. The shares were sold at an average price of $118.00, for a total transaction of $875,914.00. Following the completion of the transaction, the senior vice president now owns 33,645 shares of the company’s stock, valued at $3,970,110. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Robert T. Fraley sold 52,410 shares of Monsanto stock in a transaction on Monday, July 10th. The stock was sold at an average price of $117.95, for a total transaction of $6,181,759.50. The disclosure for this sale can be found here. Insiders have sold 74,470 shares of company stock valued at $8,791,281 in the last three months. 0.79% of the stock is owned by insiders.
Monsanto Company (Monsanto), along with its subsidiaries, is a provider of agricultural products for farmers. The Company provides seeds, biotechnology trait products, herbicides and digital agriculture tools to farmers. The Company operates through two segments: Seeds and Genomics, and Agricultural Productivity.
Receive News & Ratings for Monsanto Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monsanto Company and related companies with MarketBeat.com's FREE daily email newsletter.